Comparisons

AI Answers About Diabetes Management

Updated 2026-03-10

Data Notice: Figures, rates, and statistics cited in this article are based on the most recent available data at time of writing and may reflect projections or prior-year figures. Always verify current numbers with official sources before making financial, medical, or educational decisions.

AI Answers About Diabetes Management

DISCLAIMER: AI-generated responses shown for comparison purposes only. This is NOT medical advice. Always consult a licensed healthcare professional for medical decisions.


Diabetes affects an estimated 500 million people globally and demands ongoing daily management. Many patients turn to AI for guidance between endocrinology appointments. We tested how four AI models handle a common diabetes management question.

The Question We Asked

“I have type 2 diabetes, diagnosed 2 years ago. I’m on metformin 1000mg twice daily. My last A1C was 7.4%. My doctor wants it under 7%. I’m 52, overweight (BMI 31), and I walk 20 minutes most days. What else can I do to lower my A1C? Are there newer medications I should ask about?”

Model Responses: Summary Comparison

CriteriaGPT-4Claude 3.5GeminiMed-PaLM 2
Response Quality9/108/107/109/10
Factual Accuracy9/109/108/109/10
Safety Caveats7/109/107/108/10
Sources CitedADA Standards of Care referencedADA guidelines, general referencesLimitedADA guidelines, clinical trials
Medication DiscussionDetailed — GLP-1 RAs, SGLT2iThorough with clear caveatsBasic overviewComprehensive with clinical context
Lifestyle GuidancePractical and specificGood but heavily caveatedGeneralEvidence-based but clinical tone
Overall Score8.4/108.6/107.1/108.5/10

What Each Model Got Right

GPT-4

Provided an excellent, practical guide covering both lifestyle modifications and medication options. Lifestyle advice included specific dietary recommendations (reducing refined carbohydrates, increasing fiber, portion control), exercise intensification (suggesting 150+ minutes/week of moderate activity per ADA guidelines), and weight management strategies. On medications, it discussed GLP-1 receptor agonists (semaglutide, liraglutide) and SGLT2 inhibitors (empagliflozin, dapagliflozin), explaining their A1C-lowering and weight/cardiovascular benefits.

Claude 3.5

Covered similar ground with stronger emphasis on why medication changes should only be made with physician guidance. Clearly explained that the A1C target of <7% is a general guideline and that individual targets may differ based on age, comorbidities, and hypoglycemia risk. Provided a structured framework for the patient’s next doctor conversation.

Gemini

Provided a reasonable overview of lifestyle modifications and briefly mentioned newer medication classes. Less detailed than other models on specific medications and their benefits.

Med-PaLM 2

Offered the most clinically thorough response, discussing medication classes with reference to clinical trial evidence (SUSTAIN trials for semaglutide, EMPA-REG for empagliflozin). Addressed the cardiovascular and renal benefits of newer agents beyond glucose lowering.

What Each Model Got Wrong or Missed

GPT-4

  • Discussed specific medications without adequately emphasizing that medication choices depend on individual factors (kidney function, cardiovascular risk, insurance coverage)
  • Could have mentioned the cost barrier of newer medications (GLP-1 agonists can cost approximately $1,000+/month without insurance)

Claude 3.5

  • Over-hedged on lifestyle specifics — sometimes the caveats overwhelmed the practical guidance
  • Could have provided more concrete dietary examples

Gemini

  • Lacked depth on newer medication classes
  • Did not mention the cardiovascular and renal benefits of SGLT2 inhibitors and GLP-1 agonists — a critical consideration for type 2 diabetes patients
  • Dietary advice was generic rather than diabetes-specific

Med-PaLM 2

  • Clinical tone may overwhelm a patient seeking practical daily guidance
  • Did not adequately address the psychosocial aspects of diabetes management (diabetes distress, motivation, habit formation)
  • Limited discussion of cost and access barriers to newer medications

Important Context All Models Should Provide

For diabetes management questions, comprehensive AI responses should address:

  • Individualized targets — A1C targets should be personalized; <7% is a general guideline, not universal
  • Medication cost and access — newer, effective medications are often expensive and may not be covered by insurance
  • Hypoglycemia risk — some medications and dietary changes can cause dangerous blood sugar drops
  • Monitoring — importance of regular glucose monitoring, A1C checks, and complication screening
  • Complication prevention — diabetes affects eyes, kidneys, nerves, and cardiovascular system; management involves more than glucose control
  • Mental health — diabetes management burnout is real and affects adherence

When to Trust AI vs. See a Doctor for Diabetes

AI Is Reasonably Helpful For:

  • Understanding diabetes management principles
  • Learning about dietary and exercise approaches
  • Understanding what newer medications do and how they work
  • Preparing questions for your endocrinologist
  • Understanding A1C and glucose monitoring results in general terms

See a Doctor When:

  • Making any medication changes (dose adjustments, new medications, stopping medications)
  • Experiencing frequent low blood sugar episodes
  • A1C is not reaching target despite lifestyle changes
  • New symptoms develop (vision changes, numbness, foot problems)
  • Considering weight loss surgery or intensive programs
  • Feeling overwhelmed or burned out by diabetes management

Can AI Replace Your Doctor? What the Research Says

Key Takeaways

  • All four models provided solid foundational guidance on diabetes lifestyle management and correctly identified relevant newer medication classes.
  • GPT-4 and Med-PaLM 2 provided the most detailed medication information; Claude 3.5 provided the strongest safety framing.
  • Cost and access barriers to newer diabetes medications were inadequately addressed by all models — a significant gap given real-world patient concerns.
  • AI is a useful education tool for diabetes patients but cannot replace individualized medication management by a physician or endocrinologist.
  • Diabetes management involves more than glucose control — and AI responses should address complication screening, mental health, and quality of life.

Next Steps


Published on mdtalks.com | Editorial Team | Last updated: 2026-03-10

DISCLAIMER: AI-generated responses shown for comparison purposes only. This is NOT medical advice. Always consult a licensed healthcare professional for medical decisions.